AACP
EBS icon

Advantage Alpha Capital Partners’s Emergent Biosolutions EBS Stock Holding History

Advantage Alpha Capital Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45,936
Closed -$405K – 37
2025
Q3 		$405K Buy
+45,936
New +$357K 0.12% 111

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Advantage Alpha Capital Partners's EBS Position: Q4 2025 in Review

Advantage Alpha Capital Partners sold out of Emergent Biosolutions (EBS) in Q4 2025, closing a stake of 45,936 shares — an estimated $405K sold.

Advantage Alpha Capital Partners first reported a position in EBS in Q3 2025 and held it in 1 quarter. The position peaked at $405K in Q3 2025. 183 funds tracked by Wall St. Rank hold EBS as of Q4 2025.

  • Advantage Alpha Capital Partners reported no remaining Emergent Biosolutions position as of Q4 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 45,936 Emergent Biosolutions shares in Q4 2025, an estimated $405K.
  • Advantage Alpha Capital Partners first reported a position in Emergent Biosolutions in Q3 2025 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Emergent Biosolutions position peaked at $405K in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2025.